Business Description
Decoy Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US33938A1051
Total Employee Number:
11Description
Decoy Therapeutics Inc is a pre-clinical stage biotechnology company focused on advancing its pipeline of peptide conjugate therapeutics engineered through its proprietary IMP3ACT platform. The IMP3ACT platform represents a paradigm shift in peptide conjugate drug discovery and manufacturing, leveraging machine learning (ML) and artificial intelligence (AI" tools alongside high-speed synthesis techniques to rapidly engineer, optimize and manufacture peptide conjugates that target serious unmet medical needs. The company manages its business in one operating segment, focused on the discovery and development therapeutics for patients with high, unmet medical needs. Its pipeline programs include: Pan-Coronavirus; and Tripledemic.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.46 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 82.2 | |||||
3-Year EPS without NRI Growth Rate | 79.7 | |||||
3-Year FCF Growth Rate | 85.7 | |||||
3-Year Book Growth Rate | -87.1 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
9-Day RSI | 33.59 | |||||
14-Day RSI | 39.86 | |||||
6-1 Month Momentum % | -3.54 | |||||
12-1 Month Momentum % | -99.03 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.84 | |||||
Quick Ratio | 1.84 | |||||
Cash Ratio | 1.72 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -543.1 | |||||
Shareholder Yield % | -305.31 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -492 | |||||
ROA % | -222.35 | |||||
ROIC % | -968.69 | |||||
3-Year ROIIC % | 326.95 | |||||
ROC (Joel Greenblatt) % | -34233.77 | |||||
ROCE % | -497.55 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 1.01 | |||||
Price-to-Tangible-Book | 1.01 | |||||
EV-to-EBIT | -0.17 | |||||
EV-to-EBITDA | -0.17 | |||||
EV-to-Forward-Revenue | 1.01 | |||||
EV-to-FCF | -0.34 | |||||
| Price-to-Net-Current-Asset-Value | 1.02 | |||||
| Price-to-Net-Cash | 1.19 | |||||
Earnings Yield (Greenblatt) % | -588.24 | |||||
FCF Yield % | -167.58 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Decoy Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -106.76 | ||
| Beta | -1.1513 | ||
| 3-Year Sharpe Ratio | -1.33 | ||
| 3-Year Sortino Ratio | -1.31 | ||
| Volatility % | 123.2 | ||
| 14-Day RSI | 39.86 | ||
| 14-Day ATR (€) | 0.000872 | ||
| 20-Day SMA (€) | 5.232 | ||
| 12-1 Month Momentum % | -99.03 | ||
| 52-Week Range (€) | 4.2 - 541.44 | ||
| Shares Outstanding (Mil) | 0.53 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Decoy Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Decoy Therapeutics Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 133 days | ||
| Second quarter earnings results for 2026 | 2026-08-12 | In 40 days | ||
| General meeting for 2026 | 2026-07-14 10:00 | In 12 days | ||
| First quarter earnings results for 2026 | 2026-05-08 | 5.23 (+0.00%) | ||
| Guidance call for 2026 | 2026-04-09 16:00 | 5.23 (+0.00%) | ||
| Annual report for 2025 | 2026-03-31 | 5.23 (+0.00%) | ||
| 0.0833333:1 Stock Split | 2026-03-09 | 5.23 (+8.46%) | ||
| Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial | 2026-02-10 13:20 | 6.72 (+0.00%) | ||
| General meeting for 2025 | 2025-12-19 10:00 | 5.42 (+0.00%) | ||
| Third quarter earnings results for 2025 | 2025-11-14 | 10.08 (+0.00%) |
Show
Entries
Decoy Therapeutics Inc Frequently Asked Questions
What is Decoy Therapeutics Inc(FRA:FP11)'s stock price today?
The current price of FRA:FP11 is €5.23. The 52 week high of FRA:FP11 is €541.44 and 52 week low is €4.20.
When is next earnings date of Decoy Therapeutics Inc(FRA:FP11)?
The next earnings date of Decoy Therapeutics Inc(FRA:FP11) is 2026-08-12 Est..
Does Decoy Therapeutics Inc(FRA:FP11) pay dividends? If so, how much?
Decoy Therapeutics Inc(FRA:FP11) does not pay dividend.
Press Release
Articles on Decoy Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers